DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments | Psychedelic Invest

California’s psychedelic decriminalisation bill, SB-58, was passed with amendments by the Assembly Appropriations Committee. Its amended version will now head to the assembly floor for

September 1, 2023

Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement – Biotech Investments

Takeda Pharmaceutical Company Limited / Key word(s): Strategic Company Decision Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating

May 10, 2024

SARS-CoV-2 detected in common wildlife species

SARS-CoV-2, the virus responsible for COVID-19, is widespread among wildlife species, according to Virginia Tech research published Monday (July 29, 2024) in Nature Communications.

July 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.